Zevra Therapeutics (NASDAQ:ZVRA) CEO Neil Mcfarlane Sells 19,500 Shares of Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CEO Neil Mcfarlane sold 19,500 shares of the business’s stock in a transaction dated Friday, October 10th. The stock was sold at an average price of $10.82, for a total transaction of $210,990.00. Following the completion of the sale, the chief executive officer directly owned 222,016 shares of the company’s stock, valued at $2,402,213.12. The trade was a 8.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Zevra Therapeutics Price Performance

ZVRA opened at $11.01 on Friday. The company has a 50-day moving average of $9.40 and a 200-day moving average of $9.07. The company has a market capitalization of $617.99 million, a P/E ratio of -52.43 and a beta of 1.49. Zevra Therapeutics, Inc. has a 1-year low of $6.19 and a 1-year high of $13.16. The company has a debt-to-equity ratio of 0.52, a quick ratio of 7.81 and a current ratio of 7.85.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, August 12th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $1.43 by ($1.49). The company had revenue of $25.88 million during the quarter, compared to the consensus estimate of $22.49 million. Zevra Therapeutics had a negative return on equity of 112.40% and a net margin of 4.33%. Equities analysts expect that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analysts Set New Price Targets

ZVRA has been the subject of several research analyst reports. Zacks Research downgraded shares of Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 18th. JMP Securities lowered their price objective on shares of Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating for the company in a research report on Wednesday, August 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Zevra Therapeutics in a research report on Saturday, September 27th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 13th. Finally, HC Wainwright initiated coverage on shares of Zevra Therapeutics in a research report on Wednesday, July 2nd. They set a “buy” rating and a $26.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Zevra Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $24.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Woodline Partners LP grew its position in Zevra Therapeutics by 11.5% in the 1st quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock worth $34,571,000 after purchasing an additional 476,032 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Zevra Therapeutics by 20,564.1% in the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock worth $60,000 after acquiring an additional 8,020 shares during the period. Rhumbline Advisers lifted its stake in shares of Zevra Therapeutics by 9.6% in the 1st quarter. Rhumbline Advisers now owns 74,585 shares of the company’s stock worth $559,000 after acquiring an additional 6,532 shares during the period. Readystate Asset Management LP lifted its stake in shares of Zevra Therapeutics by 924.6% in the 1st quarter. Readystate Asset Management LP now owns 683,032 shares of the company’s stock worth $5,116,000 after acquiring an additional 616,370 shares during the period. Finally, Retirement Planning Co of New England Inc. lifted its stake in shares of Zevra Therapeutics by 6.9% in the 1st quarter. Retirement Planning Co of New England Inc. now owns 550,180 shares of the company’s stock worth $4,121,000 after acquiring an additional 35,348 shares during the period. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.